-

Primmune Therapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 32nd Annual Oppenheimer Healthcare Conference, which will be held virtually March 15 to 17.

32nd Annual Oppenheimer Healthcare Conference

Date: Tuesday, March 15
Time: 2:40 p.m. ET

More information about the conference can be found here.

About Primmune Therapeutics

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapy TherAjuvants™ for the treatment of cancers and viral diseases. For more information, please visit https://www.primmunerx.com/.

Contacts

Media Contact:
MacDougall Advisors
Matthew Corcoran
mcorcoran@macdougall.bio
617-866-7350

Industry:

Primmune Therapeutics

Release Summary
Primmune Therapeutics Announces Participation in the 32nd Annual Oppenheimer Healthcare Conference.
Release Versions
English

Contacts

Media Contact:
MacDougall Advisors
Matthew Corcoran
mcorcoran@macdougall.bio
617-866-7350

More News From Primmune Therapeutics

Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics announces the receipt of a $22.5 million grant from the Defense Threat Reduction Agency to develop a treatment for Lassa fever....

Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics presents clinical data from first-in-human, Phase 1 study of PRTX007 at the 2023 AASLD Annual Meeting....

Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics announces the upcoming presentation of new clinical data from its Phase 1 study of PRTX007 at the Annual Liver Meeting....
Back to Newsroom